Could sST2 Predict Contrast-Induced Nephropathy in ST-Segment Elevation Myocardial Infarction?

References

• Duan C, Cao Y, Liu Y, et al. A new preprocedure risk score for predicting contrast-induced acute kidney injury. Can J Cardiol. 2017;33(6):714–723. doi:10.1016/j.cjca.2017.01.01528392272
   PubMed Web of Science ®Google Scholar
• McCullough PA, Adam A, Becker CR, et al. CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):5K–13K.
   PubMed Web of Science ®Google Scholar
• Busch SV, Jensen SE, Rosenberg J, Gögenur I. Prevention of contrast-induced nephropathy in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review. J Interv Cardiol. 2013;26(1):97–105. doi:10.1111/joic.1200723240788
   PubMed Web of Science ®Google Scholar
• Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011;97(21):1753–1757. doi:10.1136/hrt.2010.21867721602521
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–1471. doi:10.1503/cmaj.104084715911862
   PubMed Web of Science ®Google Scholar
• Salvagno GL, Pavan C. Prognostic biomarkers in acute coronary syndrome. Ann Transl Med. 2016;4(13):258. doi:10.21037/atm.2016.06.3627500159
   PubMed Web of Science ®Google Scholar
• Mueller T, Jaffe AS. Soluble ST2-analytical considerations. Am J Cardiol. 2015;115(7):8B–21B. doi:10.1016/j.amjcard.2015.01.03525456867
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936–1944. doi:10.1161/CIRCULATIONAHA.107.72802218378613
   PubMed Web of Science ®Google Scholar
• Somuncu MU, Akgun T, Cakir MO, et al. The elevated soluble ST2 predicts no-reflow phenomenon in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2019;26(11):970–978. doi:10.5551/jat.4841330996145
   PubMed Web of Science ®Google Scholar
• Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399.15464318
   PubMed Web of Science ®Google Scholar
• Marenzi G, De Metrio M, Rubino M, et al. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. Am Heart J. 2010;160(6):1170–1177. doi:10.1016/j.ahj.2010.09.02221146674
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):2550–2583. doi:10.1016/j.jacc.2011.08.006
   Web of Science ®Google Scholar
• Liu Y, Chen JY, Huo Y, et al.; RESCIND group. Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): study design and protocol for the randomized, controlled trial, the ATTEMPT, RESCIND 1 (First study for reduction of contraSt-induCed nephropathy followINg carDiac catheterization) trial. Am Heart J. 2016;172:88–95.26856220
   PubMed Web of Science ®Google Scholar
• Ali A, Bhan C, Malik MB, Ahmad MQ, Sami SA. The prevention and management of contrast-induced acute kidney injury: a mini-review of the literature. Cureus. 2018;10(9):e3284.30443454
   PubMed Web of Science ®Google Scholar
• Van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury- Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018;28(7):2845–2855. doi:10.1007/s00330-017-5246-529426991
   PubMed Web of Science ®Google Scholar
• Fliser D, Laville M, Covic A, et al.; Ad-hoc working group of ERBP. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263–4272. doi:10.1093/ndt/gfs375.23045432
   PubMed Web of Science ®Google Scholar
• Firouzi A, Alemzadeh-Ansari MJ, Mohammadhadi N, et al. Association between the risks of contrast-induced nephropathy after diagnostic or interventional coronary management and the transradial and transfemoral access approaches. J Cardiovasc Thorac Res. 2020;12(1):51–55. doi:10.34172/jcvtr.2020.0832211138
   PubMed Web of Science ®Google Scholar
• Bartunek J, Delrue L, van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52(25):2166–2174. doi:10.1016/j.jacc.2008.09.02719095135
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–2966. doi:10.1161/01.CIR.0000038705.69871.D912460879
   PubMed Web of Science ®Google Scholar
• Seo SM, Kim SH, Kim Y, Yoon HE, Shin SJ. Prognostic utility of soluble suppression of tumorigenicity 2 level as a predictor of clinical outcomes in incident hemodialysis patients. Int J Med Sci. 2018;15(7):730–737. doi:10.7150/ijms.2363829910678
   PubMed Web of Science ®Google Scholar
• Jenkins WS, Roger VL, Jaffe AS, et al. Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am J Med. 2017;130(9):1112.e9–1112.e15. doi:10.1016/j.amjmed.2017.02.034
   Web of Science ®Google Scholar
• Takatori H, Makita S, Ito T, Matsuki A, Nakajima H. Regulatory mechanisms of IL-33-ST2-mediated allergic inflammation. Front Immunol. 2018;9(9):2004. doi:10.3389/fimmu.2018.0200430233590
   PubMed Web of Science ®Google Scholar
• Wu H, Yang S, Wu X, et al. Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. Biochem Biophys Res Commun. 2014;450(1):110–116. doi:10.1016/j.bbrc.2014.05.07324866242
   PubMed Web of Science ®Google Scholar
• Shao D, Perros F, Caramori G, et al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem Biophys Res Commun. 2014;451(1):8–14. doi:10.1016/j.bbrc.2014.06.11125003325
   PubMed Web of Science ®Google Scholar
• Plawecki M, Morena M, Kuster N, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: impact on risk prediction. Mediators Inflamm. 2018;2018:3952526. doi:10.1155/2018/395252630402040
   PubMed Web of Science ®Google Scholar
• Guerchicoff A, Stone GW, Mehran R, et al. Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial . Catheter Cardiovasc Interv. 2015;85(3):335–342. doi:10.1002/ccd.2562025130788
   PubMed Web of Science ®Google Scholar
• Chandiramani R, Cao D, Nicolas J, Mehran R. Contrast-induced acute kidney injury. Cardiovasc Interv Ther. 2020;35(3):209–217. doi:10.1007/s12928-020-00660-8.32253719
   PubMed Web of Science ®Google Scholar
• Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol. 2016;32(2):247–255. doi:10.1016/j.cjca.2015.05.01326277092
   PubMed Web of Science ®Google Scholar
• Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol. 2008;3:288–296.18057308
   PubMed Web of Science ®Google Scholar
• Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol. 2010;45:188–195.20195159
   PubMed Web of Science ®Google Scholar
• Clanton TL. Hypoxia-induced reactive oxygen species formation in skeletal muscle. J Appl Physiol. 2007;102(6):2379–2388. doi:10.1152/japplphysiol.01298.200617289907
   PubMed Web of Science ®Google Scholar
• Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894–903.12040355
   PubMed Web of Science ®Google Scholar
• Weir RA, Millar AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–250. doi:10.1016/j.jacc.2009.08.04720117403
   PubMed Web of Science ®Google Scholar
• Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9. doi:10.1016/j.jcin.2013.06.01624456715
   PubMed Web of Science ®Google Scholar
• Felker GM, Fiuzat M, Thompson V, et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail. 2013;6(6):1172–1179. doi:10.1161/CIRCHEARTFAILURE.113.00020724103327
   PubMed Web of Science ®Google Scholar